WO2003072195A3 - Method for administering glp-1 molecules - Google Patents

Method for administering glp-1 molecules Download PDF

Info

Publication number
WO2003072195A3
WO2003072195A3 PCT/US2003/003111 US0303111W WO03072195A3 WO 2003072195 A3 WO2003072195 A3 WO 2003072195A3 US 0303111 W US0303111 W US 0303111W WO 03072195 A3 WO03072195 A3 WO 03072195A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
glp
administering glp
administering
feasibility
Prior art date
Application number
PCT/US2003/003111
Other languages
French (fr)
Other versions
WO2003072195A2 (en
Inventor
Mohammed Amin Khan
Bryan Edward Jones
John Mcneill Mcgill
Original Assignee
Lilly Co Eli
Mohammed Amin Khan
Bryan Edward Jones
John Mcneill Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03707669.2A priority Critical patent/EP1478233B1/en
Priority to CA2473340A priority patent/CA2473340C/en
Application filed by Lilly Co Eli, Mohammed Amin Khan, Bryan Edward Jones, John Mcneill Mcgill filed Critical Lilly Co Eli
Priority to KR10-2004-7012920A priority patent/KR20040085205A/en
Priority to AU2003208945A priority patent/AU2003208945B2/en
Priority to ES03707669.2T priority patent/ES2614603T3/en
Priority to KR1020117007409A priority patent/KR101165431B1/en
Priority to US10/504,717 priority patent/US20050148497A1/en
Priority to MXPA04008068A priority patent/MXPA04008068A/en
Priority to BR0307727-6A priority patent/BR0307727A/en
Priority to NZ534125A priority patent/NZ534125A/en
Priority to JP2003570937A priority patent/JP4417113B2/en
Publication of WO2003072195A2 publication Critical patent/WO2003072195A2/en
Publication of WO2003072195A3 publication Critical patent/WO2003072195A3/en
Priority to IL163278A priority patent/IL163278A/en
Priority to ZA2004/06626A priority patent/ZA200406626B/en
Priority to US12/421,590 priority patent/US7939494B2/en
Priority to US13/004,964 priority patent/US8492330B2/en
Priority to US13/943,610 priority patent/US20140005106A1/en
Priority to IL230315A priority patent/IL230315A/en
Priority to US14/603,239 priority patent/US20150202296A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention encompasses formulations that demonstrate the feasibility of oral absorption comprising GLP-1 compounds and specified delivery agents.
PCT/US2003/003111 2002-02-20 2003-02-07 Method for administering glp-1 molecules WO2003072195A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
JP2003570937A JP4417113B2 (en) 2002-02-20 2003-02-07 Administration method of GLP-1 molecule
NZ534125A NZ534125A (en) 2002-02-20 2003-02-07 A formulation comprising a GLP-1 compound and a delivery agent
KR10-2004-7012920A KR20040085205A (en) 2002-02-20 2003-02-07 Method for administering glp-1 molecules
CA2473340A CA2473340C (en) 2002-02-20 2003-02-07 Formulations comprising a glp-1 compound and a delivery agent, and uses thereof
ES03707669.2T ES2614603T3 (en) 2002-02-20 2003-02-07 GLP-1 Molecule Administration Procedure
KR1020117007409A KR101165431B1 (en) 2002-02-20 2003-02-07 Method for administering glp-1 molecules
US10/504,717 US20050148497A1 (en) 2002-02-20 2003-02-07 Method for administering glp-1 molecules
MXPA04008068A MXPA04008068A (en) 2002-02-20 2003-02-07 Method for administering glp-1 molecules.
BR0307727-6A BR0307727A (en) 2002-02-20 2003-02-07 Fomulation
EP03707669.2A EP1478233B1 (en) 2002-02-20 2003-02-07 Method for administering glp-1 molecules
AU2003208945A AU2003208945B2 (en) 2002-02-20 2003-02-07 Method for administering GLP-1 molecules
IL163278A IL163278A (en) 2002-02-20 2004-07-29 Formulations comprising glp-1 molecules and use thereof in the preparation of medicaments
ZA2004/06626A ZA200406626B (en) 2002-02-20 2004-08-19 Method for administering glp-1 molecules
US12/421,590 US7939494B2 (en) 2002-02-20 2009-04-09 Method for administering GLP-1 molecules
US13/004,964 US8492330B2 (en) 2002-02-20 2011-01-12 Formulation comprising GLP-1
US13/943,610 US20140005106A1 (en) 2002-02-20 2013-07-16 Method for administering glp-1 molecules
IL230315A IL230315A (en) 2002-02-20 2014-01-05 Formulations comprising glp-1 molecules and 8-[(2-hydroxybenzoyl)amino]octanoic acid and use thereof in the preparation of medicaments
US14/603,239 US20150202296A1 (en) 2002-02-20 2015-01-22 Method for administering glp-1 molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35818402P 2002-02-20 2002-02-20
US60/358,184 2002-02-20

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/504,717 A-371-Of-International US20050148497A1 (en) 2002-02-20 2003-02-07 Method for administering glp-1 molecules
US10504717 A-371-Of-International 2003-02-07
US12/421,590 Continuation US7939494B2 (en) 2002-02-20 2009-04-09 Method for administering GLP-1 molecules

Publications (2)

Publication Number Publication Date
WO2003072195A2 WO2003072195A2 (en) 2003-09-04
WO2003072195A3 true WO2003072195A3 (en) 2004-03-25

Family

ID=27765952

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/003111 WO2003072195A2 (en) 2002-02-20 2003-02-07 Method for administering glp-1 molecules

Country Status (16)

Country Link
US (5) US20050148497A1 (en)
EP (2) EP2409569B1 (en)
JP (2) JP4417113B2 (en)
KR (2) KR101165431B1 (en)
CN (1) CN1332711C (en)
AU (1) AU2003208945B2 (en)
BR (1) BR0307727A (en)
CA (1) CA2473340C (en)
ES (1) ES2614603T3 (en)
IL (2) IL163278A (en)
MX (1) MXPA04008068A (en)
NZ (1) NZ534125A (en)
PL (1) PL209734B1 (en)
RU (1) RU2332229C2 (en)
WO (1) WO2003072195A2 (en)
ZA (1) ZA200406626B (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2614603T3 (en) * 2002-02-20 2017-06-01 Emisphere Technologies, Inc. GLP-1 Molecule Administration Procedure
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
DE60335608D1 (en) * 2002-02-27 2011-02-17 Pharmain Corp COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
ES2300568T3 (en) 2002-03-20 2008-06-16 Mannkind Corporation INHALATION APPARATUS
CA2532026C (en) 2003-08-20 2012-04-17 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
US20070293423A1 (en) 2003-08-20 2007-12-20 Eli Lilly And Company Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
MX2007001903A (en) 2004-08-20 2007-08-02 Mannkind Corp Catalysis of diketopiperazine synthesis.
US20090044575A1 (en) * 2004-08-23 2009-02-19 Reckitt Benckiser N.V. Detergent Dispensing Device
KR101306384B1 (en) 2004-08-23 2013-09-09 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8975227B2 (en) * 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
JP5465878B2 (en) 2005-09-14 2014-04-09 マンカインド コーポレイション Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CA2628400A1 (en) * 2005-11-07 2007-05-10 Reckitt Benckiser N.V. Dosage element
KR101872061B1 (en) 2005-12-19 2018-06-27 파마인 코포레이션 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
CA2633117A1 (en) * 2006-01-21 2007-07-26 Reckitt Benckiser N.V. Multi-dosing detergent delivery device
CN104383546B (en) 2006-02-22 2021-03-02 曼金德公司 Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent
MX2008013216A (en) * 2006-04-14 2008-10-27 Mannkind Corp Glucagon-like peptide 1(glp-1) pharmaceutical formulations.
WO2008014232A2 (en) * 2006-07-24 2008-01-31 Emisphere Technologies, Inc. Pharmaceutical formulations for the treatment of alzheimer's disease
US8895777B2 (en) 2006-08-31 2014-11-25 Emisphere Technologies Inc Compounds and compositions for delivering active agents
EP2086382A1 (en) * 2006-10-30 2009-08-12 Reckitt Benckiser N.V. Multi-dosing detergent delivery device
GB0621574D0 (en) * 2006-10-30 2006-12-06 Reckitt Benckiser Nv Multi-dosing detergent delivery device
GB0621569D0 (en) * 2006-10-30 2006-12-06 Reckitt Benckiser Nv Mounting device
GB0621576D0 (en) 2006-10-30 2006-12-06 Reckitt Benckiser Nv Device status indicator
CA2668335A1 (en) * 2006-10-30 2008-05-08 Reckitt Benckiser Production (Poland) Sp.Zo.O. Compressed detergent composition
GB0621570D0 (en) * 2006-10-30 2006-12-06 Reckitt Benckiser Nv Multi-dosing detergent delivery device
GB0621578D0 (en) * 2006-10-30 2006-12-13 Reckitt Benckiser Nv Multi-dosing detergent delivery device
GB0621572D0 (en) * 2006-10-30 2006-12-06 Reckitt Benckiser Nv Multi-dosing detergent delivery device
GB0710231D0 (en) * 2007-05-30 2007-07-11 Reckitt Benckiser Nv Refill device for multi-dosing detergent delivery device
GB0710229D0 (en) * 2007-05-30 2007-07-11 Reckitt Benckiser Nv Detergent dosing device
JP2009019027A (en) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin secretion peptide derivative in which amino acid of amino terminal is varied
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN104689432B (en) 2008-06-13 2018-07-06 曼金德公司 Diskus and the system for drug conveying
JP5479465B2 (en) 2008-06-20 2014-04-23 マンカインド コーポレイション Interactive device and method for profiling inhalation efforts in real time
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Use of ultrarapid acting insulin
EP2344519B1 (en) 2008-11-07 2016-09-28 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (en) 2009-03-11 2014-04-30 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler
EP2440184B1 (en) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CA2784757A1 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
US20130150323A1 (en) * 2010-02-04 2013-06-13 Urigen Pharmaceuticals, Inc Use of oral heparin preparations to treat urinary tract diseases and conditions
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
BR112013014942B1 (en) * 2010-12-16 2020-01-28 Novo Nordisk As solid compositions for administration, and their uses
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
ES2612278T3 (en) 2011-04-12 2017-05-16 Novo Nordisk A/S GLP-1 double-acylated derivatives
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
HUE042757T2 (en) 2012-03-22 2019-07-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
KR102072202B1 (en) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Compositions of glp-1 peptides and preparation thereof
ES2871328T3 (en) 2012-06-20 2021-10-28 Novo Nordisk As Tablet formulation comprising a peptide and a delivery agent
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
WO2014096150A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
PT2991671T (en) 2013-05-02 2018-11-05 Novo Nordisk As Oral dosing of glp-1 compounds
BR112016000937A8 (en) 2013-07-18 2021-06-22 Mannkind Corp dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation
JP2016530930A (en) 2013-08-05 2016-10-06 マンカインド コーポレイション Ventilation device and method
JP6599863B2 (en) 2013-08-15 2019-10-30 ノヴォ ノルディスク アー／エス GLP-1 derivatives and uses thereof
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
PE20181327A1 (en) 2015-12-23 2018-08-20 Amgen Inc METHOD TO TREAT OR IMPROVE METABOLIC DISORDERS WITH GASTRIC INHIBITOR PEPTIDE RECEPTOR BINDING PROTEINS (GIPR) IN COMBINATION WITH GLP-1 AGONISTS
JOP20190177A1 (en) 2017-01-17 2019-07-16 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
PE20211202A1 (en) 2017-08-24 2021-07-05 Novo Nordisk As COMPOSITIONS OF GLP-1 AND ITS USES
PL3746111T3 (en) 2018-02-02 2024-01-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI829687B (en) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
PE20221575A1 (en) 2020-02-18 2022-10-06 Novo Nordisk As PHARMACEUTICAL FORMULATIONS

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US6191102B1 (en) * 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554155A (en) * 1896-02-04 Hose-band
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
DE3729209A1 (en) 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh USE OF BEZAFIBRATE FOR TREATING DIABETES
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
JP2911496B2 (en) * 1989-09-11 1999-06-23 帝國製薬株式会社 Highly absorbable vaginal agent containing bioactive polypeptide
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JP3262329B2 (en) 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス GLP-1 analog useful for the treatment of diabetes
US5122539A (en) * 1990-02-12 1992-06-16 Center For Innovative Technology Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6221367B1 (en) * 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US6344213B1 (en) * 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
DK36392D0 (en) * 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
PL176007B1 (en) 1992-06-15 1999-03-31 Scios Inc Novel derivatives of polypeptide glp-1
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
SE9302278D0 (en) * 1992-10-28 1993-07-02 Kabi Pharmacia Ab GROWTH HORMONE
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6461643B2 (en) * 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
EP1025840B1 (en) * 1993-04-22 2005-06-29 Emisphere Technologies, Inc. Oral drug compositions
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
EP0710121B1 (en) * 1993-07-30 2000-10-11 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
WO1995005848A1 (en) 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996020005A1 (en) 1994-12-23 1996-07-04 Novo Nordisk A/S Protracted glp-1 compositions
US5565558A (en) * 1994-12-30 1996-10-15 Mccully; Kilmer S. Thioretinaco ozonide and enhanced biological activity of thioretinaco ozonide in combination with interferon
AU5360796A (en) * 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
BR9604880A (en) 1995-03-31 1998-05-19 Emisphere Tech Inc Compound composition dosage unit form methods for administering a biologically active agent for preparing a composition for administering an active agent and for preparing a compound and pharmacological composition
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
JP2001501593A (en) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド Methods for regulating gastrointestinal motility
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA72181C2 (en) 1996-08-30 2005-02-15 Ново Нордіск А/С Derivatives of glucanolike peptide-1
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
DE69732572T2 (en) 1996-11-12 2005-12-29 Novo Nordisk A/S USE OF GLP-1 PEPTIDES
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
EP1093819B1 (en) * 1997-02-07 2006-05-03 Emisphere Technologies, Inc. Compound and composition for delivering active agents
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
BR9811866A (en) 1997-08-08 2000-08-15 Amylin Pharmaceuticals Inc Exendin agonist compounds
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
DK1032587T4 (en) 1997-11-14 2013-04-08 Amylin Pharmaceuticals Llc New exendin agonist compounds
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6334213B1 (en) 1998-01-20 2001-12-25 Preview Systems Merging of separate executable computer programs to form a single executable computer program
ATE366115T1 (en) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1
ATE466027T1 (en) 1998-02-27 2010-05-15 Novo Nordisk As DERIVATIVES OF GLP-1 ANALOGUE
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6009856A (en) * 1998-05-27 2000-01-04 Caterpillar Inc. Fuel injector isolation
SE9802080D0 (en) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CN1338924A (en) 1999-01-08 2002-03-06 艾米斯菲尔技术有限公司 Polymeric delivery agents and delivery agent compounds
AU3492100A (en) 1999-02-11 2000-08-29 Emisphere Technologies, Inc. Oxadiazole compounds and compositions for delivering active agents
JP4637365B2 (en) * 1999-02-26 2011-02-23 エミスフェアー・テクノロジーズ・インク Compounds and compositions for active agent delivery
CA2369591C (en) 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
KR100788970B1 (en) 1999-11-05 2007-12-27 에미스페어 테크놀로지스, 인코포레이티드 Phenoxy carboxylic acid compounds and compositions for delivering active agents
AU2274201A (en) 1999-12-16 2001-06-25 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4879433B2 (en) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク Compounds and compositions for delivering active agents
DE60124710T2 (en) * 2000-06-16 2007-09-13 Eli Lilly And Co., Indianapolis ANALOG OF GLUCAGON SIMILAR PEPTIDE-1
BR0112311A (en) 2000-06-29 2003-09-02 Emisphere Tech Inc Active agent release compounds and compositions, unit dosage form, method for preparing said compositions and their use
CN1492763B (en) * 2001-03-01 2012-05-23 艾米斯菲尔技术有限公司 Compositions for delivering bisphosphonates
AU2002316200A1 (en) 2001-06-08 2002-12-23 Emisphere Technologies, Inc. Compound and composition for delivering active agents
CN1596248B (en) 2001-11-13 2012-05-09 艾米斯菲尔技术有限公司 Phenoxy amine compounds and compositions for delivering active agents
ES2614603T3 (en) 2002-02-20 2017-06-01 Emisphere Technologies, Inc. GLP-1 Molecule Administration Procedure
ES2465496T3 (en) 2003-01-06 2014-06-05 Emisphere Technologies, Inc. Oral nocturnal insulin therapy
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5863555A (en) * 1995-10-23 1999-01-26 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US6191102B1 (en) * 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
US6583111B1 (en) * 1996-11-05 2003-06-24 Eli Lilly And Company Use of GLP-1 analogs and derivative adminstered peripherally in regulation of obesity
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1478233A4 *

Also Published As

Publication number Publication date
RU2332229C2 (en) 2008-08-27
US20050148497A1 (en) 2005-07-07
JP2005524658A (en) 2005-08-18
EP2409569A3 (en) 2012-04-18
PL371736A1 (en) 2005-06-27
IL230315A (en) 2016-11-30
JP5657230B2 (en) 2015-01-21
EP2409569A2 (en) 2012-01-25
US20150202296A1 (en) 2015-07-23
AU2003208945B2 (en) 2008-05-01
KR20110058863A (en) 2011-06-01
EP2409569B1 (en) 2017-08-16
CA2473340C (en) 2014-12-09
US8492330B2 (en) 2013-07-23
ZA200406626B (en) 2005-11-30
ES2614603T3 (en) 2017-06-01
BR0307727A (en) 2005-01-25
CN1332711C (en) 2007-08-22
NZ534125A (en) 2006-11-30
KR101165431B1 (en) 2012-07-12
MXPA04008068A (en) 2004-11-26
EP1478233B1 (en) 2016-11-09
CN1635832A (en) 2005-07-06
CA2473340A1 (en) 2003-09-04
KR20040085205A (en) 2004-10-07
US20110178006A1 (en) 2011-07-21
US20090286735A1 (en) 2009-11-19
US20140005106A1 (en) 2014-01-02
IL163278A (en) 2014-02-27
JP4417113B2 (en) 2010-02-17
EP1478233A2 (en) 2004-11-24
AU2003208945A1 (en) 2003-09-09
US7939494B2 (en) 2011-05-10
PL209734B1 (en) 2011-10-31
RU2004127916A (en) 2005-04-10
WO2003072195A2 (en) 2003-09-04
EP1478233A4 (en) 2009-09-02
JP2010006836A (en) 2010-01-14

Similar Documents

Publication Publication Date Title
WO2003072195A3 (en) Method for administering glp-1 molecules
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2002365875A1 (en) Stent designed for the delivery of therapeautic substance or other agents
AU2003229084A1 (en) Methods and formulations for the delivery of pharmacologically active agents
HK1073997A1 (en) Administration of agents for the treatment of inflammation
AU2002322719A1 (en) Delivery of therapeutic capable agents
WO2004064769A3 (en) Methods for making and using topical delivery agents
AU2002319653A1 (en) Method for oral drug delivery
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
WO2005065318A3 (en) Effervescent oral opiate dosage form
AU2003222067A1 (en) System for delivery of therapeutic substances
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
MXPA03005980A (en) Compositions for nasal administration of insulin.
WO2005030142A8 (en) Rifalazil formulations
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2004021992A3 (en) Delivery of therapeutics to the brain and spinal cord
WO2003061572A3 (en) Anti-inflammatory formulations
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AU2002334123A1 (en) Anaesthetic compositions and method for their administration
WO2005062874A3 (en) Compounds and compositions for delivering active agents
WO2004051549A8 (en) Active agent delivery method
GB0201607D0 (en) Formulation for the administration of medicinal substances

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2473340

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003208945

Country of ref document: AU

Ref document number: 534125

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 163278

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1148/KOLNP/2004

Country of ref document: IN

Ref document number: 01148/KOLNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 10504717

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2003707669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003707669

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020047012920

Country of ref document: KR

Ref document number: 200406626

Country of ref document: ZA

Ref document number: PA/A/2004/008068

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501278

Country of ref document: PH

Ref document number: 20038043653

Country of ref document: CN

Ref document number: 2003570937

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004127916

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020047012920

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003707669

Country of ref document: EP